• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • Statistics
  • More
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
 

Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.

Options
  • Details
  • Files
BORIS DOI
10.48620/85305
Publisher DOI
10.1016/j.jinf.2025.106426
PubMed ID
39864526
Description
Background
Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.Methods
The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5-17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types.Results
Analyses included 10,168 cases <5y from PCV13 sites and 2,849 from PCV10 sites, 3,711 and 1,549 for 5-17y and 29,187 and 5,653 for ≥18y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 4874% across products and PCV7 impact strata for children <5y, 3562% for 5-17y and 036% for ≥18y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5y: 96100%; 5-17y: 7785%; ≥18y: 7385%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups.Conclusion
Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
Date of Publication
2025-03
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
Incidence
•
indirect protection
•
pneumococcal conjugate vaccines
•
pneumococcal meningitis
•
serotype replacement
•
serotypes
•
vaccine impact
Language(s)
en
Contributor(s)
Yang, Yangyupei
Knoll, Maria Deloria
Herbert, Carly
Bennett, Julia C
Feikin, Daniel R
Quesada, Maria Garcia
Hetrich, Marissa K
Zeger, Scott L
Kagucia, Eunice W
Xiao, Melody
Cohen, Adam L
van der Linden, Mark
du Plessis, Mignon
Yildirim, Inci
Winje, Brita A
Varon, Emmanuelle
Valenzuela, Maria Teresa
Valentiner-Branth, Palle
Steens, Anneke
Scott, J Anthony
Savrasova, Larisa
Sanz, Juan Carlos
Khan, Aalisha Sahu
Oishi, Kazunori
Nzoyikorera, Néhémie
Nuorti, J Pekka
Mereckiene, Jolita
McMahon, Kimberley
McGeer, Allison
Mackenzie, Grant A
MacDonald, Laura
Ladhani, Shamez N
Kristinsson, Karl G
Kleynhans, Jackie
Kellner, James D
Jayasinghe, Sanjay
Ho, Pak-Leung
Hilty, Markusorcid-logo
Institute for Infectious Diseases, Research
Hammitt, Laura L
Guevara, Marcela
Gilkison, Charlotte
Gierke, Ryan
Desmet, Stefanie
De Wals, Philippe
Dagan, Ron
Colzani, Edoardo
Ciruela, Pilar
Chuluunbat, Urtnasan
Chan, Guanhao
Camilli, Romina
Bruce, Michael G
Brandileone, Maria-Cristina C
Ampofo, Krow
O'Brien, Katherine L
Hayford, Kyla
Additional Credits
Institute for Infectious Diseases, Research
Series
Journal of Infection
Publisher
Elsevier
ISSN
1532-2742
0163-4453
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: ae9592 [15.12. 16:43]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo